Deoxycoformycin (pentostatin): Clinical pharmacology, role in the chemotherapy of cancer, and use in other diseases

Haematologia

Volumn 27, Issue 2, 1996, Pages 55-84

  Spiers, Alexander S D ^a  

^a H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

Author keywords

cancer chemotherapy; clinical pharmacology; deoxycoformycin; pentostatin; use in non malignant diseases

Indexed keywords

FLUDARABINE; PENTOSTATIN; VIDARABINE;

CANCER; CANCER CHEMOTHERAPY; CHRONIC LYMPHATIC LEUKEMIA; CLINICAL TRIAL; DRUG POTENTIATION; HUMAN; IMMUNE DEFICIENCY; IMMUNOSUPPRESSIVE TREATMENT; KERATOCONJUNCTIVITIS; KIDNEY CARCINOMA; KIDNEY FAILURE; LEUKEMIA; LYMPHOMA; MALARIA; MELANOMA; OPPORTUNISTIC INFECTION; PHARMACODYNAMICS; REVIEW; VIRUS INFECTION;

ADENOSINE DEAMINASE; ANIMALS; ANTIMETABOLITES, ANTINEOPLASTIC; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CLINICAL TRIALS; DRUG SYNERGISM; ENZYME INHIBITORS; FORECASTING; HEMATOLOGIC NEOPLASMS; HUMANS; IMMUNOSUPPRESSIVE AGENTS; KIDNEY DISEASES; MICE; MOLECULAR STRUCTURE; NEOPLASM PROTEINS; NERVOUS SYSTEM DISEASES; PENTOSTATIN; VIDARABINE;

EID: 0029962209     PISSN: 00176559     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (149)

1. Clinical Brochure: 2′-DEOXYCOFORMYCIN, NSC 218321. Investigational Drug Branch, CTEP, DCT, National Cancer Institute, Bethesda, MD, April 1979.
2. Agarwal, R. P., Spector, T., Parks R. E.: Tight-binding inhibitors - IV. Inhibition of adenosine deaminases by various inhibitors. Biochem. Pharmacol. 26, 359 (1977).
3. Evans, B., Wolfendan, R.: A potential transition state analog for adenosine deaminase. J. Am. Chem. Soc. 42, 4751 (1970).
4. Woo, P. W. K., Dion, H. W., Lange, S. M., Dahl, L. F., Durham, L. J.: A novel adenosine and ara-A deaminase inhibitor, (R)-3-(2-deoxy-B-D-erythro-pentofuranosyl)-3,6,7,8-tetrahydro-imidazo-{4,5-d} {1,3}-diazepin-8-ol. J. Heterocycl. Chem. 11, 641 (1974).
5. McConnell, W. R., Furner, R. L., Hill, D. L.: Pharmacokinetics of 2′-deoxycoformycin in normal and L1210 leukemic mice. Drug. Metab. Dispos. 7, 11 (1979).
6. Major, P. P., Agarwal, R. P., Kufe, D. W.: Clinical pharmacology of deoxycoformycin. Blood 58, 91 (1981).
7. Malspeis, L., Weinrib, A. B., Staubus, A. E., Grever, M. R., Balcerzak, S. P., Neidhart, J. A.: Clinical pharmacokinetics of 2′-deoxycoformycin. Cancer Treat. Symp. 2, 7 (1984).
8. Agarwal, R. P.: Pharmacology of 2′-deoxycoformycin and vidarabine. Cancer Treat. Symp. 2, 17 (1984).
9. Plunkett, W., Feun, L. G., Benjamin, R. S., Keating, M., Freireich, E. J.: Modulation of vidarabine metabolism by 2′-deoxycoformycin for therapy of acute leukemia. Cancer Treat. Symp. 2, 23 (1984).
10. Agarwal, R. P.: Inhibitors of adenosine deaminase. Pharmacol. Ther. 17, 399 (1982).
11. Tung, R., Silber, R., Quagliata, F., Conklyn, M., Gottesman, J., Hirschhorn, R.: Adenosine deaminase ' activity in chronic lymphocytic leukemia: relationship to B- and T-cell subpopulations. J. Clin. Invest. 57, 756 (1976).
12. Giblett, E. R., Anderson, J. E., Cohen, F.: Adenosine deaminase deficiency in two patients with severely impaired cellular immunity. Lancet. 2, 1067 (1972).
13. Smyth, J. E., Poplack, D. G., Holiman, B. J., Leventhal, B. G., Yarbro, G.: Correlation of adenosine deaminase activity with cell surface markers in acute lymphoblastic leukemia. J. Clin. Invest. 62, 710 (1978).
14. Grever, M. R., Siaw, M. F. E., Jacob, W. F., Neidhart, J. A., Miser, J. S., Coleman, M. S., Hutton, J. J., Balcerzak, S. P.: The biochemical and clinical consequences of 2′-deoxycoformycin in refractory lymphoproliferative malignancy. Blood 57, 406 (1981).
15. Spiers, A. S. D., Ruckdeschel, J. C., Horton, J.: Effectiveness of pentostatin (2′-deoxycoformycin) in refractory lymphoid neoplasms. Scand. J. Haematol. 32, 130 (1984).
16. Grever, M. R., Wilson, H. E., Kraut, E. H., Neidhart, J. A., Balcerzak, S. P.: Deoxycoformycin in the treatment of refractory chronic lymphocytic leukemia. Proc. Am. Soc. Clin. Oncol. 22, 487, abstract (1981).
17. Seegmiller, J. E., Thompson, L., Bleustein, H. et al.: Nucleotide and nucleoside metabolism and lymphocyte function. In: Biological Basis of Immunodeficiency, 251, Gelfand, E. W., Disch, H. M. (Eds), New York: Raven Press (1980).
18. Fox, R. M., Mann, G. J., Kefford, R. R: Deoxyadenosine toxicity to human peripheral blood lymphocytes: implications for 2′-deoxycoformycin as a potential immunosuppressive drug. Cancer Treat. Symp. 2, 33 (1984).
19. Siaw, M. F. E., Coleman, M. S.: Identification and quantitation of 2′-deoxycoformycin nucleotides in human lymphoblastoid cells. Cancer Treat. Symp. 2, 37 (1984).
20. Hershfield, M. S.: Effects of treatment with 2′-deoxycoformycin and vidarabine on S-adenosylhomocysteine metabolism. Cancer Treat. Sympos. 2, 29 (1984).
21. Henderson, J. F., Scott, F. W., Lowe, J. K.: Toxicity of naturally occurring purine deoxyribonucleosides. Pharmacol. Ther. 8, 573 (1980).
22. Carson, D. A., Wasson, B. B., Lakow, E. et al.: Possible metabolic basis for the different immunodeficient states associated with genetic deficiencies of adenosine deaminase and purine nucleoside phosphorylase. Proc. Natl. Acad. Sci. USA 79, 3848 (1982).
23. Kefford, R. F., Fox, R. M.: Purine deoxynucleoside toxicity in nondividing human lymphoid cells. Cancer Res. 42, 324 (1982).
24. Yu, J., Matsumoto, S. S., Yu, A. L.: Inhibition of transcription as a mechanism of lymphocytotoxicity induced by deoxyadenosine and 2′-deoxycoformycin.. Cancer Treat. Symp. 2, 75 (1984).
25. Fox, R. M., Kefford, R. F., Mann, G. J.: Mechanisms of deoxypurine nucleoside toxicity in human leukemic T-lymphoblasts. Cancer Treat. Symp. 2, 81 (1984).
26. Kefford, R. F., Fox, R. M.: Deoxycoformycin-induced response in chronic lymphocytic leukemia: deoxyadenosine toxicity in non-replicating lymphocytes. Br. J. Haematol. 50, 627 (1982).
27. Seto, S., Carrera, C. J., Kubota, M., Wasson, D. B., Carson, D. A.: Mechanism of deoxyadenosine and 2-chlorodeoxyadenosine toxicity to nondividing human lymphocytes. J. Clin. Invest. 75, 377 (1985).
28. Dearden, C. E., Matutes, E., Hoffbrand, A. V., Ganeshaguru, K. et al.: Membrane phenotype and response to deoxycoformycin in mature T cell malignancies. Br. Med. J. 295, 873 (1987).
29. Spiers, A. S. D., Lawrence, D. A., Levine, M., Weitzman, H.: T-cell chronic lymphocytic leukemias and T-cell lymphoma-leukaemia: heterogeneity and anomalous cell markers. Scand. J. Haematol. 37, 421 (1986).
30. Ho, A. D., Ganeshaguru, K., Knauf, W., Dietz, G. et al.: Clinical response to deoxycoformycin in chronic lymphoid neoplasms and biochemical changes in circulating malignant cells in vivo. Blood 72, 1884 (1988).
31. Ho, A. D., Klotzbucher, A., Gross, A., Dietz, G. et al.: Induction of intracellular and plasma 2′,5′-oligoadenylate synthetase by pentostatin. Leukemia 6, 209 (1992).
32. Ganeshaguru, K., de Mel, W. C., Sissolak, G., Catovsky, D. et al.: Increase in 2′,5′-oligoadenylate synthetase caused by deoxycoformycin in hairy cell leukaemia. Br. J. Haematol. 80, 194 (1992).
33. Lamballe, F., Le Prise, P. Y., Le Gall, E., David, J. C.: DATP-mediated inhibition of DNA ligase by 2′-deoxycoformycin in T and B cell leukemia. Leukemia 3, 97 (1989).
34. Johnston, J. B., Lee, K., Verburg, L., Blondal, J. et al.: Induction of apoptosis in CD4+ prolymphocytic leukemia by deoxyadenosine and 2′-deoxycoformycin. Leukemia Res. 16, 781 (1992).
35. Lipera, W.: Hairy-cell leukemia. N. Engl. J. Med. 317, 901 (1987).
36. Ho, A. D., Ganeshaguru, K., Knauf, W., Dietz, G. et al.: Enzyme activities of leukemic cells and bio-chemical changes induced by deoxycoformycin in vitro - lack of correlation with clinical response. Leukemia Res. 13, 269 (1989).
37. Smyth, J. F., Chassin, M. M., Harrap, K. R., Adamson, R. H., Johns, D. G.: 2′-deoxycoformycin: Phase I trial and clinical pharmacology. Proc. Am. Ass. Cancer Res. 20, 47 (1979).
38. Smyth, J. F.: Selective treatment of lymphoid malignancy with adenosine deaminase inhibitors. Enzyme defects and immune dysfunction. Ciba Foundation Symp. 68, 263 (1979).
39. Prentice, H. G., Smyth, J. F., Ganeshaguru, K., Wonke, B. et al.: Remission induction with adenosine-deaminase inhibitor 2′-deoxycoformycin in Thy-lymphoblastic leukaemia. Lancet 2, 170 (1980).
40. Prentice, H. G., Russell, N. H., Lee, N., Ganeshaguru, K. et al.: Therapeutic selectivity of and prediction of response to 2′-deoxycoformycin in acute leukaemia. Lancet 2, 1250 (1981).
41. Poplack, D. G., Sallan, S. E., Rivera, G., Holcenberg, J. et al.: Phase I study of 2′-deoxycoformycin in acute lymphoblastic leukemia. Cancer Res. 41, 3343 (1981).
42. Giblett, E. R., Anderson, J. E., Cohen, F., Pollara, B., Meuwissen, H. J.: Adenosine-deaminase deficiency in two patients with severely impaired cellular immunity. Lancet 2, 1067 (1972).
43. Meuwissen, H. J., Pollara, B., Pickering, R. J.: Combined immunodeficiency disease asociated with adenosine deaminase deficiency. J. Pediat. 86, 169 (1975).
44. Kanofsky, J. R., Baron, J. M., Roth, D. G., Sweet, D. L. et al.: Treatment of lymphoid malignancies with 2′-deoxycoformycin: a pilot study. Am. J. Clin. Oncol. (CCT) 5, 179 (1982).
45. Spiers, A. S. D., Ruckdeschel, J. C., Horton, J., Rauch, A. E. et al.: Effectiveness of pentostatin (2′-deoxycoformycin, DCF) in refractory lymphoid neoplasms. Blood 60 (Suppl. 1), 163a (1982).
46. Murphy, S. B., Sinkule, J., Rivera, G.: Clinical and biochemical pharmacologic observations of the effects of constant intravenous infusions of 2′-deoxycoformycin (DCF) in children with refractory acute lymphoblastic leukemia. Blood 60 (Suppl. 1), 157a (1982).
47. Spiers, A. S. D.: Experience with 2′-deoxycoformycin in treatment of refractory leukemias and lymphomas. Cancer Treat. Symp. 2, 51 (1984).
48. Spiers, A. S. D., Ruckdeschel, J. C., Horton, J.: Effectiveness of pentostatin (2′-deoxycoformycin) in refractory lymphoid neoplasms. Scand. J. Haematol. 32, 130 (1984).
49. Cummings, F. J., Kim, K., Neiman, R. S., Comis, R. L. et al.: Phase II trial of pentostatin in refractory lymphomas and cutaneous T-cell disease. J. Clin. Oncol. 9, 565 (1991).
50. Gray, D. P., Grever, M. R., Siaw, M. F. E., Coleman, M.S., Balcerzak, S. P.: 2′-deoxycoformycin and 9-beta-D-arabinofuranosyladenine in the treatment of refractory acute myelocytic leukemia. Proc. Am. Soc. Clin. Oncol. 22, 488, C-606 (1988).
51. Miser, J. S., Grever, M. R., Coleman, M. S., Poplack, D. G. et al.: Deoxycoformycin (DCF) and adenine arabinoside (ARA-A) in the treatment of acute lymphoblastic leukemia (ALL) - biochemical correlations. Blood 60 (Suppl. 1), 157a (1982).
52. Kufe, D. W.: Clinical and cellular pharmacology of 2′-deoxycoformycin and vidarabine. Cancer Treat. Symp. 2, 85 (1984).
53. Grever, M. R., Malspeis, L., Kraut, E. H., Wilson, H. E. et al.: Combination of 2′-deoxycoformycin and vidarabine in advanced malignancy: clinical and biochemical observations. Cancer Treat. Symp. 2, 97 (1984).
54. White, E. L., Shaddix, S. C., Brockman, R. W. et al.: Comparison of the actions of 9-beta-D-arabinofuranosyl-2-fluoroadenine and 9-beta-D-arabinofuranosyladenine on target enzymes from mouse tumor cells. Cancer Res. 42, 2260 (1982).
55. Data on file, Berlex Corporation.
56. Spiers, A. S. D., Parekh, S. J.: Pentostatin (2′-deoxycoformycin, DCF) is active in hairy cell leukemia (HCL). Blood 62 (Suppl. 1), 208a, 737 (1983).
57. Spiers, A. S. D., Parekh, S. J.: Complete remission in hairy cell leukaemia achieved with pentostatin. Lancet 1, 1080 (1984).
58. Spiers, A. S. D., Parekh, S. J., Bishop, M. B.: Hairy-cell leukemia: Induction of complete remission with pentostatin (2′-deoxycoformycin). J. Clin. Oncol. 2, 1336 (1984).
59. Spiers, A. S. D.: The activity of deoxycoformycin (pentostatin) in refractory leukemias and lymphomas. Ann. N. Y. Acad. Sci. 451, 138 (1985).
60. Spiers, A. S. D., Parekh, S. J., Ramnes, C. R., Cassileth, P. A., Oken, M. M.: Hairy cell leukemia (HCL): pentostatin (dCF, 2′-deoxycoformycin) is effective both as initial treatment and after failure of splenectomy and α-interferon. Blood 66 (Suppl. 1), 208a (1985).
61. Spiers, A. S. D., De Conti, R. C., Parekh, S. J., Ramnes, C. R., Oken, M. M.: Hairy cell leukemia (HCL): pentostatin (dCF, 2′-deoxycoformycin) as primary therapy, and after failure of splenectomy and aplha interferon (IFN). Proc. Am. Soc. Clin. Oncol. 5, 151, 591 (1986).
62. Spiers, A. S. D., Moore, D., Cassileth, P. A. et al.: Remissions in hairy-cell leukemia with pentostatin (2′-deoxycoformycin). N. Engl. J. Med. 316, 825 (1987).
63. Spiers, A. S. D., Parekh, S. J.: The treatment of hairy cell leukemia with 2′-deoxycoformycin: results in India and in the United States. Leukemia 1, 347 (1987).
64. Spiers, A. S. D., Parekh, S. J.: Treatment of hairy cell leukemia (HCL) with pentostatin (2′-deoxycoformycin, dCF): five-year follow-up. The dose intensity may affect the durability of complete remission (CR). Occurrence of a second malignancy after dCF therapy. Blood 72 (Suppl. 1), 228a (1988).
65. Spiers, A. S. D.: The role of pentostatin (2′-deoxycoformycin, dCF) in the management of lymphoproliferative malignancies. Blood Reviews 1, 106 (1987).
66. Spiers, A. S. D., Parekh, S. J.: Hairy cell leukemia 9HCL): complete remission for six years following treatment with pentostatin (2′-deoxycoformycin, dCF) and induction of a second complete remission with retreatment. Blood 76 (Suppl. 1), 323 (1990).
67. Cassileth, P. A., Cheuvart, B., Spiers, A. S. D. et al.: Pentostatin induces durable remissions in hairy cell leukemia. J. Clin. Oncol. 9, 243 (1991).
68. Kraut, E. H., Bouroncle, B. A., Grever, M. R.: Low-dose deoxycoformycin in the treatment of hairy cell leukemia. Blood 68, 1119 (1986).
69. Johnston, J. B., Glazer, R. I., Pugh, L., Israels, L. G.: The treatment of hairy-cell leukaemia with 2′-deoxycoformycin. Br. J. Haematol. 63, 525 (1986).
70. Grem, J. L., King, S. A., Cheson, B. D. et al.: Pentostatin in hairy cell leukemia: treatment by the special exception mechanism. J. Nat. Cancer Inst. 81, 448 (1989).
71. Martin, A., Nerenstone, S., Urba, W. J. et al.: Treatment of hairy cell leukemia with alternating cycles of pentostatin and recombinant leukocyte A interferon: results of a Phase II study. J. Clin. Oncol. 8, 721 (1990).
72. Habermann, T. M., Andersen, J. W., Cassileth, P. A. et al.: Sequential administration of recombinant interferon alpha and deoxycoformycin in the treatment of hairy cell leukemia. Br. J. Haematol. 80, 466 (1992).
73. Golomb, H. M., Fefer, A., Golde, D. W. et al.: Report of a multi-institutional study of 193 patients with hairy cell leukemia treated with interferon alpha-2b. Semin. Oncol. 15, 7 (1988).
74. Ratain, M. J., Golomb, H. M., Bardawil, R. G. et al.: Durability of responses to interferon alfa-2b in advanced hairy cell leukemia. Blood 69, 872 (1987).
75. Golomb, H. M., Ratain, M. J., Fefer, A. et al.: Randomized study of the duration of treatment with interferon alfa-2b in patients with hairy cell leukemia. J. Natl. Cancer Inst. 80, 369 (1988).
76. Sorensen, J. M., Chun, H. G., Vena, D. et al.: Pentostatin (DCF) therapy for hairy cell leukemia (HCL): update of a group C protocol of 208 patients (PTS) who have failed interferon alpha (IFNA). Proc. Am. Soc. Clin. Oncol. 10, A787 (1991).
77. (a) Ho, A. D., Thaler, J., Lauria, F. et al.: Complete remissions induced by deoxycoformycin in hairy cell leukemia refractory to interferon alpha. Proc. Am. Soc. Clin. Oncol. 8, A773 (1989).
78. (b) Ho, A. D., Thaler, J., Mandelli, F. et al.: Response to pentostatin in hairy-cell leukemia refractory to interferon-alpha. J. Clin. Oncol. 7, 1533 (1989).
79. Holland, D. R., Cannors, J. M., Gascoyne, R. D.: Superior quality and duration of response to deoxycoformycin in hairy cell leukemia patients previously exposed to alpha-interferon. Proc. Am. Soc. Clin. Oncol. 9, A782 (1990).
80. Grever, M., Kopecky, K., Head, D. et al.: A randomized comparison of deoxycoformycin (DCF) vs alpha-2a interferon (IFN) in previously untreated patients with hairy cell leukemia (HCL): and NCI-sponsored intergroup study (SWOG, ECOG, CALGB, NCIC CTG). Proc. Am. Soc. Clin. Oncol. 11, A868 (1992).
81. Piro, L. D., Carrera, C. J., Carson, D. A. et al.: Lasting remissions in hairy-cell leukemia induced by a single infusion of 2-chlorodeoxyadenosine. N. Engl. J. Med. 322, 1117 (1990).
82. Saven, A., Piro, L.: Newer purine analogues for the treatment of hairy-cell leukemia. N. Engl. J. Med. 330, 691 (1994).
83. Saven, A., Piro, L. D.: Complete remissions in hairy cell leukemia with 2-chlorodeoxyadenosine after failure with 2′-deoxycoformycin. Ann. Intern. Med. 119, 278 (1993).
84. Grever, M. R., Siaw, M. F. E., Jacob, W. F. et al.: The biochemical and clinical consequences of 2′-deoxycoformycin in refractory lymphoproliferative malignancy. Blood 57, 406 (1981).
85. Grever, M. R., Wilson, H. E., Kraut, E. H. et al.: Deoxycoformycin in the treatment of refractory chronic lymphocytic leukemia. Proc. Am. Soc. Clin. Oncol. 22, 487, C-605 (1981).
86. Grever, M. R., Laiby, J. M., Kraut, E. H. et al.: Low-dose deoxycoformycin in lymphoid malignancy. J. Clin. Oncol. 3, 1196 (1985).
87. Gribbin, T. E.: New purine analogues for the treatment of chronic B-cell malignancies. Henry Ford Hosp. Med. J. 39, 98 (1991).
88. Ho, A. D., Thaler, J., Stryckmans, P. et al.: Pentostatin in resistant chronic lymphocytic leukemia - a Phase II trial of the European Organization for Research and Treatment of Cancer. Proc. Am. Soc. Clin. Oncol. 9, A797 (1990).
89. Cheson, B. D.: Current approaches to the chemotherapy of B-cell chronic lymphocytic leukemia: a review. Am. J. Hematol. 32, 72 (1989).
90. Yu, A., Bakay, B., Matsumoto, S. et al.: The effects of deoxycoformycin (DCF) on T-cell chronic lymphocytic leukemia (CLL). Proc. Am. As. Cancer Res. 22, 226, 894 (1981).
91. Spiers, A. S. D., Mangan, K. F., Levine, M., Biele, L.: T-cell chronic lymphocytic leukemia (T-CLL) with unique cell phenotype, intradermal bleeding, and dramatic response to deoxycoformycin (DCF). Blood 58 (Suppl. 1), 153a (1981).
92. Spiers, A. S. D., Davis, M. P., Levine, M. et al.: T-cell chronic lymphocytic leukemia: anomalous cell markers, variable morphology, and marked responsiveness to pentostatin (2′-deoxycoformycin). Scand. J. Haematol. 34, 57 (1985).
93. Adler, M. J., Hershberg, R., Yu, A.: Helper-suppressor T-cell leukemia: unusual phenotype controlled with low-dose deoxycoformycin. Am. J. Hematol. 36, 208 (1991).
94. Daenen, S., Rojer, R. A., Smit, J. W. et al.: Sucessful chemotherapy with deoxycoformycin in adult T-cell lymphoma-leukaemia. Br. J. Haematol. 58, 723 (1984).
95. Yamaguchi, K., Yul, L. S., Oda, T. et al.: Clinical consequences of 2′-deoxycoformycin treatment in patients with refractory adult T-cell leukaemia. Leukemia Res. 10, 989 (1986).
96. Lofters, W., Campbell, M., Gibbs, W. N., Cheson, B. D.: 2′-deoxycoformycin therapy in adult T-cell leukemia/lymphoma. Cancer 60, 2605 (1987).
97. El'Agnaf, M. R., Ennis, K. E., Morris, T. C. M. et al.: Successful remission induction with deoxycoformycin in elderly patiants with T-helper prolymphocytic leukemia. Br. J. Haematol. 63, 93 (1986).
98. Matutes, E., Brito-Babapulle, V., Swansbury, J. et al.: Clinical and laboratory features of 78 cases of T-prolymphocytic leukemia. Blood 78, 3269 (1991).
99. Dohner, H., Ho, A. D., Thaler, J. et al.: Pentostatin in prolymphocytic leukemia: Phase II trial of the European Organization for Research and Treatment of Cancer Leukemia Cooperative Study Group. J. Nat. Cancer Inst. 85, 658 (1993).
100. Grever, M. R., Bisaccia, F., Scarborough, D. A. et al.: An investigation of 2′-deoxycoformycin in the treatment of cutaneous T-cell lymphoma. Blood 61, 279 (1983).
101. Grever, M. R., Chapman, R. A., Ratanatharathorn, V., Slease, R. B.: An investigation of 2′-deoxycoformycin in advanced cutaneous T cell lymphoma (CTCL). Blood 66 (Suppl. 1), 215a, 744 (1985).
102. Foss, F., Fischmann, A., Schechter, G. et al.: Phase II trial of pentostatin and interferon-alfa-2a in advanced mycosis fungoides/Sezary syndrome (MF/SS). Proc. Am. Soc. Clin. Oncol. 8, A1077 (1989).
103. Foss, F., Fishmann, A., Schechter, G. et al.: Phase II trial of human interferon alfa-2a and pentostatin in advanced stage mycosis fungoides/Sezary syndrome. Proc. Am. Soc. Clin. Oncol. 9, A1005 (1990).
104. Venner, P., Eisenhauer, E. A., Wierzbicki, R., Johnson, J.: Phase II study of 2′-deoxycoformycin in patients with renal cell carcinoma. A National Cancer Institute of Canada Clinical Trials Group study. Invest. New Drugs 9, 273 (1991).
105. Witte, R. S., Walsh, C., Fisher, H. et al.: Evaluation of deoxycoformycin in patients with advanced renal cell carcinoma. Invest. New Drugs 10, 49 (1992).
106. Grever, M. R., Brager, P., Kraut, E., Metz, E.: Phase II trial of deoxycoformycin in malignant melanoma. Proc. Am. Ass. Cancer Res. 31, A1181 (1990).
107. Belch, A. R., Brox, L. W., Henderson, J. F.: Deoxycoformycin (DCF) in refractory multiple myeloma. Blood 60 (Suppl. 1), 160a, 567 (1982).
108. Gray, D. P., Grever, M. R., Siaw, M. F. E. et al.: 2′-deoxycoformycin and arabinofuranosyladenine in the treatment of refractory acute myelocytic leukemia. Proc. Am. Soc. Clin. Oncol. 22, 488, C-606 (1981).
109. Cummings, F. J., Tsiatis, A., O'Connell, M., Creech, R.: Phase H trial of low dose 2′-deoxycoformycin in refractory mallignant lymphomas. Proc. Am. Ass. Cancer Res. 27, 197, 783 (1986).
110. Ho, A. D., Thaler, J., Willemze, R. et al.: Pentostatin (2′-deoxycoformycin) for chronic lymphoid neoplasms. J. Chemother Infect Dis. Malignancies (Suppl. 1), A383 (1989).
111. Bernard, S., Gill, P., Gavigan, M. et al.: Deoxycoformycin and α-interferon in the treatment of hematologic malignancies: a Phase I study. Proc. Am. Ass. Clin. Oncol. 8, 264, 1029 (1989).
112. Dearden, C., Matutes, E., Catovsky, D.: Deoxycoformycin in the treatment of mature T-cell leukaemias. Br. J. Cancer 64, 903 (1991).
113. Seymour, J. F., O'Brien, S., Kurzrock, R. et al.: A Phase-I study of seven day continuous infusion deoxycoformycin (DCF). Proc. Am. Soc. Clin. Oncol. 13, 390, 1328 (1994).
114. Trotta, P. P., Tedde, A., Ikehara, S., et al.: Specific immunosuppressive effects of constant infusion of 2′-deoxycoformycin. Cancer Res. 41, 2189 (1981).
115. Burgess, F. W., Mell, M., Parks, R. E.: Prevention of adjuvant-induced arthritis (AA) in Wistar rats by prolonged infusion of the tight-binding adenosine deaminase (ADA) inhibitor, 2′-deoxycoformycin (dCF). Pharmacologist 26, 110, 113 (1984).
116. Kraut, E. H., Neff, J., Gochnour, D., Grever, M. R.: Immunosuppressive effets of pentostatin. Proc. Am. Soc. Clin. Oncol. 8, 183, 710 (1989).
117. Urba, W. J., Baseler, M. W., Kopp, W. C. et al.: Deoxycoformycin-induced immunosuppression in patients with hairy cell leukemia. Blood 73, 38 (1989).
118. Ho, A. D., Mannel, D. N., Wulf, G. et al.: Long-term effects of 2′-deoxycoformycin treatment on cytokine production in patients with hairy cell leukemia. Leukemia 4, 584 (1990).
119. Parke-Davis Corporation. Nipent (pentostatin for injection) Package Insert. October 1991.
120. Grem, J. L., King, S. A., Chun, H. G., Grever, M. R.: Cardiac complications observed in elderly patients following 2′-deoxycoformycin therapy. Am. J. Hematol. 38, 245 (1991).
121. Gryn, J., Gordon, R., Bapat, A. et al.: Pentostatin increases the acute toxicity of high dose cyclophosphamide. Bone Marrow Transplant 12, 217 (1993).
122. O'Dwyer, P. J., King, S. A., Eisenhauer, E. et al.: Hypersensitivity reactions to pentostatin. Cancer Chemother Pharmacol 23, 173 (1989).
123. Murphy, S. B., Herrod, H. G., Sinkule, J. A. et al.: Severe combined immunodeficiency and profound weight loss associated with chronic intermittent administration of 2′-deoxycoformycin. Cancer Treat. Symp. 2, 63 (1984).
124. Fredholm, B. B., Hedqvist, P.: Modulation of neurotransmission by purine nucleotides and nucleosides. Biochem. Pharmacol. 29, 1635 (1980).
125. Daly, J. W., Bruns, R. F., Snyder, S. H.: Adenosine receptors in the central nervous system: relationship to the central actions of methylxanthines. Life Sciences 28, 2083 (1981).
126. Skolnick, P., Paul, S. M., Marangos, P. J.: Purines as endogenous ligands of the benzodiazepine receptor. Federation Proc. 39, 3050 (1980).
127. Phillis, J. W.: Diazepam potentiation of purinergic depression of central neurons. Can. J. Physiol. Pharmacol. 57, 432 (1979).
128. Koller, C. A., Mitchell, B. S.: Erythrocyte adenosine triphosphate and deoxyadenosine triphosphate measurements predict toxicity following 2′-deoxycoformycin therapy. Cancer Treat. Symp. 2, 67 (1984).
129. Murphy, S. B., Sinkule, J. A., Rivera, G.: Phase I-II clinical and pharmacodynamic study of effects of 2′-deoxycoformycin administered by continuous infusion in children with refractory acute lymphoblastic leukemia. Cancer Treat. Symp. 2, 55 (1984).
130. Grever, M. R., Coleman, M. S., Gray, D. P. et al.: Definition of safe, effective dosing regimen of 2′-deoxycoformycin with biochemical investigation. Cancer Treat. Symp. 2, 43 (1984).
131. Spiers, A. S. D., Ruckdeschel, J. C., Horton, J.: Infections in patients treated with pentostatin (2′-deoxycoformycin, DCF) for lymphoproliferative malignancies. Blood 62 (Suppl. 1), 216a, 767 (1983).
132. O'Dwyer, P. J., Spiers, A. S. D., Marsoni, S.: Association of severe and fatal infections and treatment with pentostatin. Cancer Treat. Rep. 70, 1117 (1986).
133. Klohs, W. D., Kraker, A. J.: Pentostatin: future directions. Pharmacol. Reviews 44, 459 (1992).
134. Dillman, R. O.: A new chemotherapeutic agent: deoxycoformycin (pentostatin). Sem. Hematol. 31, 16 (1994).
135. Kraut, E. H., Grever, M. R., Bouroncle, B. A.: Long-term follow-up of patients with hairy cell leukemia after treatment with 2′-deoxycoformycin. Blood 84, 4061 (1994).
136. Annino, L., Ferrari, A., Giona, F., Cimino, G., Crescenzi, S., Cava, M. C., Pacchiarotti, A., Mandelli, R: Deoxycoformycin induces long-lasting remissions in hairy cell leukemia: clinical and biological results of two different regimens. Leukemia & Lymphoma 14 (Suppl. 1), 115 (1994).
137. Grever, M., Kopecky, K., Foucar, M. K., Head, D., Bennett, J. M., Hutchison, R. E., Corbett, W. E. N., Cassileth, P. A., Habermann, T., Golomb, H., Rai, K., Eisenhauer, E., Appelbaum, F., Cheson, B. D.: Randomized comparison of pentostatin versus interferon alfa-2a in previously untreated patients with hairy cell leukemia: an Intergroup study. J. Clin. Oncol. 13, 974 (1995).
138. Golomb, H. M.: Do we know the treatment of choice for hairy cell leukemia? Ann. Oncol. 5, 676 (1994).
139. Arena, F. P.: Treatment of hairy cell leukemia in a decade of change. Appraisal of cummunity based oncologists' opinions. Leukemia & Lymphoma 14 (Suppl. 1), 85 (1994).
140. Pagano, L., Barbera, E. O., Voso, M. T., Zollino, M., Laurenti, L., Marra, R., Leone, G.: Salvage chemotherapy with pentostatin in prolymphocytic leukemia. Haematologica 79, 542 (1994).
141. Tobinai, K., Shimoyama, M., Tajima, K., Kozuru, M., Tomonaga, M., Araki, K., Kasai, M., Takatsuki, K., Tara, M., Hotta, T., Mikuni, C.: Deoxyccoformycin (DCF)-containing combination chemotherapy for adult T-cell leukemia-lymphoma (ATL): Japan Clinical Oncology Group (JCOG) study #9109. Proc. Am. Soc. Clin. Oncol. 14, 390, 1217 (1995).
142. Mercieca, J., Matutes, E., Dearden, C., MacLennan, K., Catovsky, D.: The role of pentostatin in the treatment of T-cell malignancies: analysis of response rate in 145 patients according to disease subtype. J. Clin. Oncol. 12, 2588 (1994).
143. Saven, A.: Comparative efficacy of the newer nucleosides (fludarabine, 2′-deoxycoformycin, and 2-chlorodeoxy-adenosine) in the treatment of indolent lymphoid malignancies. Sem. Hematol. 30, 31 (1993).
144. Johnston, J. B., Williams, M., Verburg, L. et al.: Combination therapy with deoxyadenosine plus 2′-deoxycoformycin and alkylating agents. Proc. Am. Ass. Cancer Res. 34, A1765 (1993).
145. Estey, E., Thall, P., Andreeff, M. et al.: Use of granulocyte colony-stimulating factor before, during and after fludarabine plus cytarabine induction therapy of newly diagnosed acute myelogenous leukemia or myelodysplastic syndromes: comparison with fludarabine plus cytarabine without granulocyte colony-stimulating factor. J. Clin. Oncol. 12, 671 (1994).
146. Dighiero, G.: Potential immunological action of purine nucleoside analogues. Drugs 47, 57 (1994).
147. Agarwal, R. P., Busso, M. E., Mian, A. M. et al.: Uptake of 2′, 3′-dideoxyadenosine in human immunodeficiency virus-infected and noninfected human cells. AIDS Res. Hum. Retroviruses 5, 541 (1989).
148. Cheson, B. D., Vena, D. A., Foss, F. M., Sorensen, J. M.: Neurotoxicity of purine analogs: A review. J. Clin. Oncol. 12, 2216 (1994).
149. Phillis, J. W., O'Regan, M. H.: Deoxycoformycin antagonizes ischemia-induced neuronal degeneration. Brain. Res. Bull. 22, 537 (1989).